Recombinant humanised anti-PD-1 monoclonal antibody (JS001) treatment for patients with refractory or metastatic nasopharyngeal carcinoma: preliminary results of an open-label, phase 1b/2, clinical study
机构:[1]Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, State Key Lab Oncol South China,Collaborat Innova, Guangzhou, Guangdong, Peoples R China;临床科室其他部门内科华南肿瘤学国家重点实验室中山大学肿瘤防治中心[2]Shanghai First Peoples Hosp, Canc Ctr, Shanghai, Peoples R China;[3]Linyi Tumor Hosp, Dept Med Oncol, Linyi, Peoples R China;[4]Peking Univ, Dept Digest Oncol, Canc Hosp, Beijing, Peoples R China;[5]Harbin Med Univ, Dept Med Oncol, Affiliated Tumour Hosp, Harbin, Heilongjiang, Peoples R China;[6]Wuhan Tongji Hosp, Dept Oncol, Wuhan, Hubei, Peoples R China;其他科室肿瘤科华中科技大学同济医学院附属同济医院[7]Shantou Univ, Dept Med Oncol, Affiliated Tumour Hosp, Med Coll, Shantou, Peoples R China;[8]Zhejiang Univ, Dept Med Oncol, Affiliated Hosp 1, Med Coll, Hangzhou, Zhejiang, Peoples R China;内科系统肿瘤内科浙江大学医学院附属第一医院[9]Sichuan Univ, Canc Ctr, West China Hosp, Chengdu, Sichuan, Peoples R China;[10]Fudan Univ, Tumor Hosp, Shanghai, Peoples R China;[11]Fujian Med Univ, Dept Med Oncol, Union Hosp, Fuzhou, Peoples R China;[12]Henan Canc Hosp, Dept Med Oncol, Zhengzhou, Henan, Peoples R China内科第一医学部肿瘤内科河南省肿瘤医院